> when the PPS fell thirty cents after the dilution his paper loses were over 300,000$ a very percetage of his yearly salary,,,,think he liked that<
Well, considering his guaranteed take-home salary isn't a function of the share price, I don't think the paper losses on his stack of options causes him insomnia.
I think it is rare for the management of a start-up biotech to have their remuneration strongly tied to the stock price. Most get paid handsomely regardless of stock performance, and GTCB doesn't appear to be an exception.
Market Data 
Markets 
AI
